Cel Sci Corp (New York Stock Exchange Arca:CVM)
| Market Cap | 14.84M-78.5% |
| Revenue (ttm) | 0 |
| Net Income | -22.70M+10.7% |
| EPS | -2.58+74.2% |
| Shares Out | 6.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Aug 28, 1996 |
| Volume | 46,320 |
| Open | 2.10 |
| Previous Close | 2.13 |
| Day's Range | 2.10 - 2.19 |
| 52-Week Range | 0.89 - 10.39 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Dec 23, 2026 |
CEL SCI CORP has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About CVM
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CVM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CVM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CVM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CVM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CVM Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Stock-based compensation | $1.35M | 62.42% |
| Public & investor relation costs | $333.00K | 15.41% |
| Legal & accounting fees | $287.00K | 13.28% |
| Supplies & materials | $192.00K | 8.89% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CVM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CVM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CVM
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $740.24K |
| VXFVanguard Extended Market ETF | $139.54K |
| SILXETFMG Prime 2x Daily Junior Silver Miners ETF | $33.48K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $20.00K |
| VALTETFMG Sit Ultra Short ETF | $17.80K |
| GERMETFMG Treatments, Testing and Advancements ETF | $14.65K |
Estimated from each fund’s disclosed top holdings × AUM
CVM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CVM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score